Pancreatic Ductal Adenocarcinoma Cell Models for Research

Pancreatic ductal adenocarcinoma (PDAC) is the most common pancreatic malignancy, accounting for over 90% of all pancreatic cancers. According to the World Health Organization (WHO) GLOBOCAN 2022 database, pancreatic cancer is the 12th most common cancer worldwide, with approximately 511,000 new cases and 467,000 deaths annually. The incidence is nearly equal to mortality, reflecting a devastating prognosis. The National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) program reports a 5-year relative survival rate of only 12.5% for all stages combined, and for metastatic disease, the 5-year survival drops to 3%. Key risk factors include tobacco smoking, chronic pancreatitis, diabetes mellitus, obesity, and a family history of pancreatic cancer. The late diagnosis, aggressive biology, and resistance to conventional therapies underscore the urgent need for improved preclinical models.

PDAC is an ideal disease for mechanistic studies due to its well-characterized genetic landscape, the availability of extensive public datasets (e.g., TCGA, COSMIC), and the presence of distinct molecular subtypes (classical, basal-like, immunogenic, and stromal-rich). The disease is driven by a small set of high-frequency mutations (KRAS, TP53, SMAD4, CDKN2A) that are amenable to CRISPR-based gene editing. Open questions include the role of tumor heterogeneity, the tumor microenvironment, and mechanisms of therapy resistance. Gene-edited cell models enable precise dissection of these pathways, facilitating the development of targeted therapies and biomarkers.

PDAC pathogenesis involves several key pathways that are frequently deregulated:

• • KRAS/MAPK pathway: Activating mutations in KRAS (most commonly G12D, G12V, G12R) lead to constitutive activation of the RAS-RAF-MEK-ERK cascade, promoting cell proliferation and survival.
• • TP53 pathway: Loss-of-function mutations in TP53 (over 70% of cases) disrupt cell cycle arrest, apoptosis, and DNA damage repair.
• • TGF-β/SMAD4 pathway: Inactivation of SMAD4 (about 50% of cases) leads to loss of growth inhibition and increased invasiveness.
• • Cell cycle regulation: Deletion or mutation of CDKN2A (p16) occurs in about 90% of cases, leading to uncontrolled cell cycle progression.

These pathways are interconnected, and their combined alterations drive tumor initiation and progression.

The following table summarizes the most common genetic alterations in PDAC, based on data from The Cancer Genome Atlas (TCGA) and the Catalogue of Somatic Mutations in Cancer (COSMIC):

Beyond the core mutations, PDAC exhibits deregulation of several signaling networks:

• • Wnt/β-catenin pathway: Overactivation in a subset of PDAC, contributing to stemness and metastasis.
• • PI3K/AKT/mTOR pathway: Frequently activated downstream of KRAS, promoting cell survival and metabolism.
• • Hedgehog signaling: Aberrant activation in the stroma, influencing tumor-stroma crosstalk.
• • Notch signaling: Involved in epithelial-to-mesenchymal transition (EMT) and therapy resistance.
• • DNA damage repair (DDR): Defects in homologous recombination (e.g., BRCA1/2) create vulnerabilities to PARP inhibitors.

Key nodes include:

• • KRAS, BRAF, MEK, ERK (MAPK cascade)
• • TP53, MDM2, ATM (cell cycle and DNA damage)
• • SMAD4, TGFBR1/2 (TGF-β signaling)
• • PTEN, PIK3CA, AKT, mTOR (PI3K pathway)

Common PDAC cell lines and their key mutations are listed below. Organoids (3D cultures) derived from patient tumors retain genetic and phenotypic heterogeneity and are valuable for drug testing.

Organoid advantages: recapitulate tumor architecture, maintain patient-specific mutations, and allow co-culture with stromal cells.

Animal models are essential for studying PDAC in vivo:

• • Patient-derived xenografts (PDX): Implantation of patient tumor tissue into immunodeficient mice; preserves tumor heterogeneity but lacks immune system.
• • Genetically engineered mouse models (GEMM): e.g., KrasLSL-G12D/+; Trp53LSL-R172H/+; Pdx-1-Cre (KPC) model, which recapitulates human PDAC progression.
• • Induced models: Use of chemical carcinogens (e.g., azaserine) or orthotopic injection of cell lines.
• • Syngeneic models: Implantation of mouse PDAC cell lines into immunocompetent mice, useful for immunotherapy studies.

CRISPR-based gene editing enables the creation of isogenic cell lines that differ only in a specific genetic alteration, providing a controlled system to study gene function. For PDAC, common models include:

• • TP53 knockout lines: Generated by CRISPR-mediated disruption of TP53 in wild-type or KRAS-mutant backgrounds.
• • KRAS G12D knock-in lines: Introduction of the G12D mutation into a KRAS wild-type cell line (e.g., BxPC-3) to study oncogenic activation.
• • SMAD4 knockout lines: Used to investigate TGF-β signaling and metastasis.
• • Reporter lines: e.g., GFP-tagged KRAS or luciferase reporters for tracking tumor growth.

These models are commercially available from various sources, with sequence-verified clones and quality control, accelerating research. However, it is important to validate the absence of off-target effects and confirm the desired genotype.

Gene-edited cell lines are used to validate the function of genes implicated in PDAC. For example:

• • Knockout of tumor suppressors (e.g., TP53, SMAD4) in non-malignant pancreatic ductal epithelial cells to assess their role in transformation.
• • Knock-in of oncogenic KRAS mutations to study downstream signaling and metabolic reprogramming.
• • CRISPR screens using pooled libraries to identify genes essential for cell survival, proliferation, or metastasis.

Isogenic pairs (e.g., KRAS wild-type vs. KRAS G12D) are powerful tools for drug screening:

• • Differential drug response: Identify compounds that selectively kill mutant cells.
• • Resistance modeling: Expose cells to increasing drug concentrations to identify resistance mechanisms, such as secondary mutations or pathway reactivation.
• • Combination therapy testing: Evaluate synergistic effects of drugs targeting different pathways.

CRISPR-based synthetic lethality screens can identify vulnerabilities in PDAC cells with specific mutations. For example:

• • BRCA2-deficient cells are sensitive to PARP inhibitors, a clinically validated synthetic lethal interaction.
• • KRAS-mutant cells may be dependent on specific kinases or metabolic enzymes, which can be targeted therapeutically.
• • Gene-edited models help validate candidate biomarkers for patient stratification.

The following databases provide valuable genomic, transcriptomic, and functional data for PDAC research: